NCT02794467 - Placebo-controlled Proof of Concept Study of Epelsiban in Women With Adenomyosis | Biotech Hunter

Timeline

Start Date

July 31, 2016

Primary Completion Date

October 31, 2016

Study Completion Date

October 31, 2016

Conditions

Adenomyosis

Interventions

DRUG

Epelsiban

Epelsiban will be supplied as modified capsule shaped, white coated, oral tablet with a unit dose strength of 25 or 150 mg; to be taken with food or immediately after a meal, without chewing

DRUG

Placebo

A matching placebo will be supplied as modified capsule shaped, white coated, oral tablet; to be taken with food or immediately after a meal, without chewing.

Trial Locations (13)

15206

GSK Investigational Site, Pittsburgh

20036

GSK Investigational Site, Washington D.C.

27612

GSK Investigational Site, Raleigh

27713

GSK Investigational Site, Durham

33409

GSK Investigational Site, West Palm Beach

45322

GSK Investigational Site, Englewood

61820

GSK Investigational Site, Champaign

68510

GSK Investigational Site, Lincoln

70006

GSK Investigational Site, Metairie

70471

GSK Investigational Site, Mandeville

77030

GSK Investigational Site, Houston

89128

GSK Investigational Site, Las Vegas

08648

GSK Investigational Site, Lawrenceville